UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Decade-long bacterial community dynamics in cystic fibrosis airways

Proceedings of the National Academy of Sciences - PNAS, 2012-04, Vol.109 (15), p.5809-5814

2012

Volltextzugriff (PDF)

Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis

PloS one, 2018-03, Vol.13 (3), p.e0194060-e0194060

2018

Volltextzugriff (PDF)

Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment

Journal of cystic fibrosis, 2016-03, Vol.15 (2), p.147-157

2016

Volltextzugriff (PDF)

Improvements in Lung Function and Height among Cohorts of 6-Year-Olds with Cystic Fibrosis from 1994 to 2012

The Journal of pediatrics, 2014-12, Vol.165 (6), p.1091-1097.e2

2014

Volltextzugriff (PDF)

Challenges to the optimisation of cystic fibrosis exacerbation treatment outcomes

The European respiratory journal, 2024-06, Vol.63 (6)

2024

Volltextzugriff (PDF)

The march towards CFTR modulator access for all people with CF: The end of the beginning

Journal of cystic fibrosis, 2021-03, Vol.20 (2), p.185-187

VanDevanter, Donald R

2021

Volltextzugriff (PDF)

Retracing changes in cystic fibrosis understanding and management over the past twenty years

Journal of cystic fibrosis, 2022-01, Vol.21 (1), p.3-9

2022

Volltextzugriff (PDF)

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations

Respiratory research, 2010-10, Vol.11 (1), p.137-137, Article 137

2010

Volltextzugriff (PDF)

Clinical applications of pulmonary delivery of antibiotics

Advanced drug delivery reviews, 2015-05, Vol.85, p.1-6

2015

Volltextzugriff (PDF)

Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations

Journal of cystic fibrosis, 2023-09, Vol.22 (5), p.864-867

2023

Volltextzugriff (PDF)

Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes

The European respiratory journal, 2020-04, Vol.55 (4), p.2000105

2020

Volltextzugriff (PDF)

CFTR modulator theratyping: Current status, gaps and future directions

Journal of cystic fibrosis, 2019-01, Vol.18 (1), p.22-34

2019

Volltextzugriff (PDF)

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review

Journal of cystic fibrosis, 2019-03, Vol.18 (2), p.236-243

2019

Volltextzugriff (PDF)

Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections

Clinical infectious diseases, 2019-10, Vol.69 (10), p.1812-1816

2019

Volltextzugriff (PDF)

Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies

Current opinion in pulmonary medicine, 2017-11, Vol.23 (6), p.530-535

2017

Volltextzugriff (PDF)

Corrigendum to FEV1 Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function [The Journal of Pediatrics (2016) 116–121]

The Journal of pediatrics, 2023-04, Vol.255, p.265-265

2023

Volltextzugriff (PDF)

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials

Journal of cystic fibrosis, 2021-01, Vol.20 (1), p.39-45

2021

Volltextzugriff (PDF)

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities

Annals of the American Thoracic Society, 2019-05, Vol.16 (5), p.534-539

2019

Volltextzugriff (PDF)

Defining antimicrobial resistance in cystic fibrosis

Journal of cystic fibrosis, 2018-11, Vol.17 (6), p.696-704

2018

Volltextzugriff (PDF)

The Elusive Role of Airway Infection in Cystic Fibrosis Exacerbation

Journal of the Pediatric Infectious Diseases Society, 2022-09, Vol.11 (Supplement_2), p.S40-S45

2022

Volltextzugriff (PDF)

Anti-PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection

Pediatric pulmonology, 2014-07, Vol.49 (7), p.650-658

2014

Volltextzugriff (PDF)

Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis

Annals of the American Thoracic Society, 2024-05, Vol.21 (5), p.716-726

2024

Volltextzugriff (PDF)

Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens

Journal of clinical microbiology, 2016-03, Vol.54 (3), p.613-619

2016

Volltextzugriff (PDF)

The Pitfalls of Polypharmacy and Precision Medicine in Cystic Fibrosis

Annals of the American Thoracic Society, 2019-07, Vol.16 (7), p.819-820

2019

Volltextzugriff (PDF)

Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis

Pediatric pulmonology, 2020-03, Vol.55 (3), p.828-834

2020

Volltextzugriff (PDF)

1 – 25 von 115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(114)
Buchkapitel
(1)

Sprache

Englisch
(115)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(94)
Life Sciences & Biomedicine
(85)
Humans
(70)
Respiratory System
(62)
Cystic Fibrosis
(52)
Male
(40)
Female
(37)
Adult
(28)
Cystic Fibrosis - Drug Therapy
(27)
Adolescent
(26)
Anti-Bacterial Agents - Therapeutic Use
(23)
Child
(23)
Cystic Fibrosis - Physiopathology
(22)
Pediatrics
(21)
Pulmonary/respiratory
(21)
Cystic Fibrosis - Complications
(19)
Antibiotics
(18)
Biological And Medical Sciences
(18)
Disease Progression
(17)
Pseudomonas Infections - Drug Therapy
(16)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Decade-long bacterial community dynamics in cystic fibrosis airways

Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis

Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment

Improvements in Lung Function and Height among Cohorts of 6-Year-Olds with Cystic Fibrosis from 1994 to 2012

Challenges to the optimisation of cystic fibrosis exacerbation treatment outcomes

The march towards CFTR modulator access for all people with CF: The end of the beginning

Retracing changes in cystic fibrosis understanding and management over the past twenty years

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations

Clinical applications of pulmonary delivery of antibiotics

Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations

Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes

CFTR modulator theratyping: Current status, gaps and future directions

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review

Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections

Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies

Corrigendum to FEV1 Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function [The Journal of Pediatrics (2016) 116–121]

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities

Defining antimicrobial resistance in cystic fibrosis

The Elusive Role of Airway Infection in Cystic Fibrosis Exacerbation

Anti-PcrV antibody in cystic fibrosis: A novel approach targeting Pseudomonas aeruginosa airway infection

Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis

Culture-Based and Culture-Independent Bacteriologic Analysis of Cystic Fibrosis Respiratory Specimens

The Pitfalls of Polypharmacy and Precision Medicine in Cystic Fibrosis

Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis

Suchergebnisse filtern